Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study (Q38377029)

From Wikidata

Jump to navigation Jump to search

scientific article published on May 2017

Language	Label	Description	Also known as
English	Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study	scientific article published on May 2017

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

14 June 2018

http://europepmc.org/abstract/PMC/5971365

Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study (English)

1 reference

Europe PubMed Central

PMC publication ID

14 June 2018

http://europepmc.org/abstract/PMC/5971365

multiple sclerosis

1 reference

based on heuristic

inferred from title

relapsing-remitting multiple sclerosis

1 reference

based on heuristic

inferred from title

author name string

Ralph Hb Benedict

1

1 reference

Europe PubMed Central

PMC publication ID

14 June 2018

http://europepmc.org/abstract/PMC/5971365

Stanley Cohan

2

1 reference

Europe PubMed Central

PMC publication ID

14 June 2018

http://europepmc.org/abstract/PMC/5971365

Sharon G Lynch

3

1 reference

Europe PubMed Central

PMC publication ID

14 June 2018

http://europepmc.org/abstract/PMC/5971365

Katherine Riester

4

1 reference

Europe PubMed Central

PMC publication ID

14 June 2018

http://europepmc.org/abstract/PMC/5971365

Ping Wang

5

1 reference

Europe PubMed Central

PMC publication ID

14 June 2018

http://europepmc.org/abstract/PMC/5971365

Wanda Castro-Borrero

6

1 reference

Europe PubMed Central

PMC publication ID

14 June 2018

http://europepmc.org/abstract/PMC/5971365

Jacob Elkins

7

1 reference

Europe PubMed Central

PMC publication ID

14 June 2018

http://europepmc.org/abstract/PMC/5971365

Guido Sabatella

8

1 reference

Europe PubMed Central

PMC publication ID

14 June 2018

http://europepmc.org/abstract/PMC/5971365

publication date

9 May 2017

1 reference

Europe PubMed Central

PMC publication ID

14 June 2018

http://europepmc.org/abstract/PMC/5971365

Multiple Sclerosis Journal

1 reference

Europe PubMed Central

PMC publication ID

14 June 2018

http://europepmc.org/abstract/PMC/5971365

24

1 reference

Europe PubMed Central

PMC publication ID

14 June 2018

http://europepmc.org/abstract/PMC/5971365

6

1 reference

Europe PubMed Central

PMC publication ID

14 June 2018

http://europepmc.org/abstract/PMC/5971365

795-804

1 reference

Europe PubMed Central

PMC publication ID

14 June 2018

http://europepmc.org/abstract/PMC/5971365

Information processing speed in multiple sclerosis: Past, present, and future

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5971365

23 June 2018

Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5971365

23 June 2018

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5971365

23 June 2018

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5971365

23 June 2018

Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5971365

23 June 2018

Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5971365

23 June 2018

The thalamus and multiple sclerosis: modern views on pathologic, imaging, and clinical aspects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5971365

23 June 2018

Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5971365

23 June 2018

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5971365

23 June 2018

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5971365

23 June 2018

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5971365

23 June 2018

Reliable screening for neuropsychological impairment in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5971365

23 June 2018

Analyzing incomplete longitudinal clinical trial data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5971365

23 June 2018

A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5971365

23 June 2018

Neuropsychologic status in multiple sclerosis after treatment with glatiramer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5971365

23 June 2018

Analysis of covariance using the rank transformation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5971365

23 June 2018

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5971365

23 June 2018

Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5971365

23 June 2018

Practice effect in Symbol Digit Modalities Test in multiple sclerosis patients treated with natalizumab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5971365

31 August 2018

Localized atrophy of the thalamus and slowed cognitive processing speed in MS patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5971365

31 August 2018

Cognitive dysfunction in patients with multiple sclerosis treated with different types of interferon beta: a randomized clinical trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5971365

31 August 2018

Reliability and equivalence of alternate forms for the Symbol Digit Modalities Test: implications for multiple sclerosis clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5971365

31 August 2018

The effect of natalizumab on cognitive function in patients with relapsing-remitting multiple sclerosis: preliminary results of a 1-year follow-up study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5971365

31 August 2018

Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5971365

31 August 2018

Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5971365

31 August 2018

Screening for cognitive impairment in multiple sclerosis using the Symbol digit Modalities Test.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5971365

31 August 2018

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5971365

31 August 2018

Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5971365

31 August 2018

Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS

1 reference

https://pubmed.ncbi.nlm.nih.gov/28485186

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thalamic atrophy and cognition in multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/28485186

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of immunomodulatory treatment with subcutaneous interferon beta-1a oncognitive decline in mildly disabled patients with relapsing—remitting multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/28485186

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Characterizing cognitive function during relapse in multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/28485186

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cognitive dysfunction in multiple sclerosis.: II. Impact on employment and social functioning

1 reference

https://pubmed.ncbi.nlm.nih.gov/28485186

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1177/1352458517707345

1 reference

Europe PubMed Central

PMC publication ID

14 June 2018

http://europepmc.org/abstract/PMC/5971365

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 June 2018

http://europepmc.org/abstract/PMC/5971365

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 June 2018

http://europepmc.org/abstract/PMC/5971365

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38377029&oldid=1756633495"